Skip to content

Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant

Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00456040
Enrollment
25
Registered
2007-04-04
Start date
2007-03-31
Completion date
2007-03-31
Last updated
2007-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Keywords

amyloidosis, heart failure, heart transplant, stem cell transplant

Brief summary

The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.

Detailed description

Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation. The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased. Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant. We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.

Interventions

None listed

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with amyloidosis * NYHA class III or IV heart failure * Patients undergoing heart transplant evaluation * Patients less than 18 years of age

Exclusion criteria

* Patients who have unstable pulse and blood pressure

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026